CDK2 and cancer: Prior studies regarding Dp44mT, DFO, and deferasirox have demonstrated that the inhibitory effects on cancer cell proliferation and metastasis of these three drugs were mediated by several pathways, such as increasing levels of apoptosis markers including p21, p53, and activation of mitogen-activated protein kinases (MAPKs), and decreasing levels of cyclins and cyclin-dependent kinase 2 (CDK2) [8,10,11].